Muvalaplin

Muvalaplin
Clinical data
Other namesLY3473329
Identifiers
  • (2S)-3-[3-[[bis[[3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl]methyl]amino]methyl]phenyl]-2-[(3R)-pyrrolidin-3-yl]propanoic acid
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
KEGG
ChEMBL
PDB ligand
Chemical and physical data
FormulaC42H54N4O6
Molar mass710.916 g·mol−1
3D model (JSmol)
  • C1CNC[C@H]1[C@H](CC2=CC(=CC=C2)CN(CC3=CC=CC(=C3)C[C@@H]([C@H]4CCNC4)C(=O)O)CC5=CC=CC(=C5)C[C@@H]([C@H]6CCNC6)C(=O)O)C(=O)O
  • InChI=InChI=1S/C42H54N4O6/c47-40(48)37(34-10-13-43-22-34)19-28-4-1-7-31(16-28)25-46(26-32-8-2-5-29(17-32)20-38(41(49)50)35-11-14-44-23-35)27-33-9-3-6-30(18-33)21-39(42(51)52)36-12-15-45-24-36/h1-9,16-18,34-39,43-45H,10-15,19-27H2,(H,47,48)(H,49,50)(H,51,52)/t34-,35-,36-,37-,38-,39-/m0/s1
  • Key:BRLGERLDHZRETI-BGBFCPIGSA-N

Muvalaplin is an investigational new drug that is being evaluated in clinical trials for the treatment of cardiovascular disease associated with elevated lipoprotein(a) levels.

References

  1. ↑ De Los Reyes C, Rikhi RR, Doherty S, Hernandez S, Mirzai S, Shapiro MD, et al. (December 2025). "Current Clinical Trials for Treating Elevated Lipoprotein(a)". Current Cardiovascular Risk Reports. 19 (1) 7. doi:10.1007/s12170-025-00759-8. PMC 12282488. PMID 40703143.
  2. ↑ Hooper AJ, Fernando PM, Burnett JR (January 2024). "Potential of muvalaplin as a lipoprotein(a) inhibitor". Expert Opinion on Investigational Drugs. 33 (1): 5–7. doi:10.1080/13543784.2024.2302592. PMID 38186354.
  3. ↑ Diaz N, Perez C, Escribano AM, Sanz G, Priego J, Lafuente C, et al. (May 2024). "Discovery of potent small-molecule inhibitors of lipoprotein(a) formation". Nature. 629 (8013): 945–950. doi:10.1038/s41586-024-07387-z. PMC 11111404. PMID 38720069.